Swiss Parenterals Limited — Ceftriaxone Exporter Profile
Indian Pharmaceutical Exporter · #14 for Ceftriaxone · $4.6M export value · DGFT Verified
Swiss Parenterals Limited is the #14 Indian exporter of Ceftriaxone with $4.6M in export value and 154 verified shipments. Swiss Parenterals Limited holds a 1.6% market share in Ceftriaxone exports across 22 countries. The company exports 18 pharmaceutical products worth $15.9M across 9 therapeutic categories.
Swiss Parenterals Limited — Ceftriaxone Export Profile: Buyers & Destinations
Where Does Swiss Parenterals Limited Export Ceftriaxone?
| Country | Value | Shipments | Share |
|---|---|---|---|
| MEXICO | $984.9K | 25 | 27.8% |
| PERU | $777.2K | 32 | 22.0% |
| NIGERIA | $483.1K | 16 | 13.6% |
| SENEGAL | $371.2K | 12 | 10.5% |
| GHANA | $179.2K | 7 | 5.1% |
| SWITZERLAND | $163.7K | 7 | 4.6% |
| BENIN | $85.3K | 2 | 2.4% |
| PHILIPPINES | $77.3K | 18 | 2.2% |
| BOTSWANA | $54.5K | 7 | 1.5% |
| VENEZUELA | $45.2K | 2 | 1.3% |
Swiss Parenterals Limited exports Ceftriaxone to 24 countries. The largest destination is MEXICO accounting for 27.8% of Swiss Parenterals Limited's Ceftriaxone shipments, followed by PERU (22.0%) and NIGERIA (13.6%). These destinations reflect Swiss Parenterals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Ceftriaxone from Swiss Parenterals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| TO THE ORDER OF | TEMOR LESTE | $1.3M | 62 |
| TO THE ORDER | MEXICO | $927.8K | 30 |
| TO THE ORDER OF | PERU | $485.7K | 16 |
| TO THE ORDER OF . | SENEGAL | $139.1K | 6 |
| TO THE ORDER OF, | NAMIBIA | $120.0K | 6 |
| TO THE ORDER OF | THAILAND | $73.9K | 11 |
| TO THE ORDER OF FIRST GULF LIBYAN B | LIBYAN | $39.4K | 1 |
| SOCIETE GENERALE GH ANA PLC | GHANA | $32.1K | 1 |
| TO THE ORDER OF. | PERU | $30.0K | 3 |
| TO THE ORDER OF . | KAZAKISTAN | $15.1K | 3 |
Swiss Parenterals Limited supplies Ceftriaxone to 11 buyers globally. The largest buyer is TO THE ORDER OF (TEMOR LESTE), followed by TO THE ORDER (MEXICO) and TO THE ORDER OF (PERU). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Ceftriaxone Export Value and How Much Does Swiss Parenterals Limited Contribute?
India exported $98.3M worth of Ceftriaxone through 11,257 shipments from 850 suppliers to 162 countries, serving 2,555 buyers globally. Swiss Parenterals Limited contributes $4.6M to this total, accounting for 1.6% of India's Ceftriaxone exports. Swiss Parenterals Limited ships Ceftriaxone to 24 countries through 11 buyers.
What Is the Average Shipment Value for Swiss Parenterals Limited's Ceftriaxone Exports?
Swiss Parenterals Limited's average Ceftriaxone shipment value is $29.6K per consignment, based on 154 shipments totaling $4.6M. The largest destination is MEXICO (27.8% of Swiss Parenterals Limited's Ceftriaxone exports).
How Does Swiss Parenterals Limited Compare to Other Indian Ceftriaxone Exporters?
Swiss Parenterals Limited ranks #14 among 850 Indian Ceftriaxone exporters with a 1.6% market share. The top 3 exporters are INNOVA CAPTAB LIMITED ($30.0M), AUROBINDO PHARMA LTD ($9.2M), CIPLA LIMITED ($6.7M). Swiss Parenterals Limited processed 154 shipments to 22 destination countries.
What Ceftriaxone Formulations Does Swiss Parenterals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE-CEFTRIAXONE FOR INJ USP 1GM FILLED IN CLEAR MOULDED GLASS VIAL USP | $484.1K | 26 |
| PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE - STERILE CEFTRIAXONE SODIUM USP INJ CONTAINING CEFTRIAXONE NOT LENOS | $231.1K | 9 |
| PHARMACEUTICALS GOODS/HARMLESS MEDICINESFOR HUMAN USE - STERILE CEFTRIAXONE SODIUM USP INJ CONTAINING CEFTRIAXONE NOT LNOS | $179.8K | 6 |
| PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE - STERILE CEFTRIAXONE SODIUM USP INJ CONTAINING CEFTRIAXONE NOT LE | $159.9K | 4 |
| PHARMACEUTICALS GOODS/HARMLESS MEDICINESFOR HUMAN USE-STERILE CEFTRIAXONE SODIUM USP INJ CONTAINING CEFTRIAXONE NOT LESNOS | $128.2K | 3 |
| PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE-JAWA CEFTRIAXONE 1GM COMBIPACK OF CEFTRIAXONE FOR INJ USP 1GM AND | $126.7K | 4 |
| ZENSIF COMBIPACK OF CEFTRIAXONE FOR INJ. | $114.1K | 3 |
| 10ML VIAL CLEAR MOULDED TYPE III ZENSIFCEFTRIAXONE FOR INJECTION USP 1 GM DETAIL AS PER DOCUMENT | $100.0K | 2 |
| PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE - ZENSIF CEFTRIAXONE FORINJECTION USP 1 GM | $97.9K | 2 |
| PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE-STERILE CEFTRIAXONE SODIUMUSP INJECTION CONTAINING CEFTRIAXONE NO | $95.1K | 3 |
Swiss Parenterals Limited exports 71 distinct Ceftriaxone formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE-CEFTRIA with 26 shipments worth $484.1K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Ceftriaxone to Key Markets
What Swiss Parenterals Limited must comply with to export Ceftriaxone to its top destination countries
Mexico — COFEPRIS
Approval Process
Generic registration under Mexican health law. NOM standards apply.
Timeline: 12–18 months
GMP & Export Requirements
Mexican GMP (NOM-059-SSA1); COFEPRIS overseas inspection or PIC/S certificate
Sanitary Import Permit from COFEPRIS; import licence via SAT
Note: COFEPRIS participates in PIC/S, easing recognition of PIC/S certificates from Indian authorities.
Nigeria — NAFDAC
Approval Process
Drug registration under NAFDAC guidelines. WHO-type CPP from India required.
Timeline: 6–18 months
GMP & Export Requirements
WHO GMP compliance; NAFDAC conducts overseas plant inspections
Certificate of Pharmaceutical Product (CPP) from CDSCO India; NAFDAC import permit
Note: India is the largest pharma supplier to Nigeria. NAFDAC has intensified Indian site inspections.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Swiss Parenterals Limited Compare to Nearest Ceftriaxone Exporters?
Exporters ranked immediately above and below #14 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 12 | SCOTT-EDIL ADVANCE RESEARCH LABORATORIES & EDUCATI | $5.0M | 163 | 9 | $30.4K |
| 13 | NECTAR LIFE SCIENCES LIMITED | $4.9M | 115 | 15 | $42.6K |
| 14 | SWISS PARENTERALS LIMITED ★ | $4.6M | 154 | 22 | $29.6K |
| 7 | SAKAR HEALTHCARE LIMITED | $4.2M | 83 | 16 | $50.0K |
| 15 | VENUS REMEDIES LIMITED | $4.0M | 232 | 30 | $17.3K |
Swiss Parenterals Limited ranks #14 among 850 Indian Ceftriaxone exporters. Average shipment value of $29.6K compared to the market average of $115.6K. The closest competitors by value are SCOTT-EDIL ADVANCE RESEARCH LABORATORIES & EDUCATI and NECTAR LIFE SCIENCES LIMITED.
Which Indian Ports Ship Ceftriaxone Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 1,199 | 10.7% |
| JNPT/ NHAVA SHEVA SEA | 819 | 7.3% |
| JNPT | 675 | 6.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 547 | 4.9% |
| DELHI AIR CARGO ACC (INDEL4) | 472 | 4.2% |
| MUNDRA SEA | 460 | 4.1% |
| DELHI AIR | 457 | 4.1% |
| SAHAR AIR | 451 | 4.0% |
What Other Advanced Antibiotics Products Does Swiss Parenterals Limited Export?
Swiss Parenterals Limited also exports these advanced antibiotics products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Swiss Parenterals Limited's Ceftriaxone Exports
The current geopolitical climate presents both challenges and opportunities for Indian pharmaceutical exporters like Swiss Parenterals. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, causing increased freight costs and extended delivery times. Such maritime challenges can significantly impact the timely distribution of pharmaceuticals, especially to Middle Eastern markets. (pharmaceuticalcommerce.com)
Conversely, escalating US-China trade tensions have prompted the United States to diversify its import sources, potentially benefiting Indian exporters. However, recent US tariff policies, including a 25% tariff on Indian imports due to geopolitical alignments, pose a substantial challenge, potentially affecting nearly 55% of India's exports to the US. (apnews.com)
In the European Union, stringent regulatory frameworks like the Falsified Medicines Directive necessitate compliance with rigorous safety and quality standards. For companies like Swiss Parenterals, adhering to these regulations is crucial to maintain and expand their presence in EU markets.
Swiss Parenterals Limited — Regulatory Compliance & Quality Standards
The global pharmaceutical industry is witnessing heightened scrutiny regarding quality and compliance. Indian exporters, including Swiss Parenterals, must navigate complex regulatory environments, ensuring adherence to FDA, WHO, and EU GMP standards. The US FDA's increased inspections of Indian facilities underscore the importance of maintaining high-quality manufacturing practices to avoid potential export bans or recalls. (fact.net.in)
Swiss Parenterals' integration into Eris Lifesciences is expected to bolster its compliance infrastructure, leveraging Eris's established quality management systems to meet international regulatory requirements effectively.
About Swiss Parenterals Limited
Swiss Parenterals Limited exports 18 products worth $15.9M. Beyond Ceftriaxone, top products include Meropenem, Prednisolone, Fosfomycin, Methylprednisolone, Hydrocortisone. View the complete Swiss Parenterals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Ceftriaxone — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Ceftriaxone shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Swiss Parenterals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 161 individual customs records matching Swiss Parenterals Limited exporting Ceftriaxone, covering 71 formulations to 24 countries via 11 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 162+ countries, 2,555+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Ceftriaxone Export Data from Swiss Parenterals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Swiss Parenterals Limited's Ceftriaxone exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Swiss Parenterals Limited
Full Company Profile →
18 products · $15.9M total trade · 9 categories
Ceftriaxone Stats
Company Overview
Top Products by Swiss Parenterals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Swiss Parenterals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Ceftriaxone. For current shipment-level data, contact TransData Nexus.